Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director | June 20, 2017 | June 22, 2017 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Commercial | September 02, 2026 | September 03, 2026 |
| SCYNEXIS INCSCYX · Entity 7194 | Director | July 02, 2018 | July 03, 2018 |
| Sio Gene Therapies Inc.AXON · Entity 130622 | Principal Operating Officer | April 07, 2017 | April 11, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date June 20, 2017 · Filed June 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.78 · Expires 2027-06-19 | Direct | 14,000 |
Reported balance
After 2017-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-20 · Grant · Acquired 14,000 · Balance 14,000 F1: The option vests in full on June 20, 2018 subject to the Reporting Person's continued service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on June 20, 2018 subject to the Reporting Person's continued service to the Issuer through such date.
REGENERON PHARMACEUTICALS, INC.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,003 |
Ending reported balance
After 2026-09-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-02 · Sale · Disposed 1,215 · Balance 13,134 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026. Row 2 · 2026-09-03 · Sale · Disposed 1,131 · Balance 12,003 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 219 |
Reported balance
Holding disclosure · report date 2026-09-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 219 |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026.
SCYNEXIS INC
Report date July 02, 2018 · Filed July 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2028-07-01 | Direct | 9,217 |
Reported balance
After 2018-07-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-02 · Grant · Acquired 9,217 · Balance 9,217 F1: Stock option received by the Reporting Person pursuant to such Reporting Person's election to receive stock option in lieu of the Reporting Person's annual cash retainers (paid quarterly) under the Compensation Arrangement with Non-Employee Directors policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock option received by the Reporting Person pursuant to such Reporting Person's election to receive stock option in lieu of the Reporting Person's annual cash retainers (paid quarterly) under the Compensation Arrangement with Non-Employee Directors policy.
Sio Gene Therapies Inc.
Report date April 07, 2017 · Filed April 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.13 · Expires 2027-04-07 | Direct | 465,000 |
Reported balance
After 2017-04-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-04-07 · Grant · Acquired 465,000 · Balance 465,000 F1: 25% of the common shares underlying the option vest and become exercisable on April 7, 2018; the balance of the common shares vest in a series of 12 successive equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Vesting is subject to acceleration in specified circumstances, including a change in control of the Issuer or the Reporting Person's termination without cause or resignation for good reason. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the common shares underlying the option vest and become exercisable on April 7, 2018; the balance of the common shares vest in a series of 12 successive equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Vesting is subject to acceleration in specified circumstances, including a change in control of the Issuer or the Reporting Person's termination without cause or resignation for good reason.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MEDIVATION, INC.
Report date September 28, 2016 · Filed September 30, 2016
Section 16 reporting ended · disclosed 2016-09-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2016-09-28 · Other · Disposed 541 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F2: Represents shares purchased through the Issuer's Employee Stock Purchase Plan on September 21, 2016. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2016-09-28 · Disposition to issuer · Disposed 40,453 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F3: Represents unvested restricted stock units (the "RSUs") that were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.58 · Expires 2026-02-16 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-09-28 · Disposition to issuer · Disposed 80,905 · Balance 0 F4: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.
F2: Represents shares purchased through the Issuer's Employee Stock Purchase Plan on September 21, 2016.
F3: Represents unvested restricted stock units (the "RSUs") that were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger.
F4: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2019 Filed Dec 13, 2019 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 1,463 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000030 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · SVP Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,963 F1 · kind: Award of Restricted Stock under the Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 11, 2021 and 50% on December 11, 2023. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $381.40 | $0.00 |
DisclosureSEC source: 0001708138-18-000030 · edgardoc.xml · derivative · entry 2 McCourt Marion · CIK 0001663758 · SVP Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-12-12 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-18-000030 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · SVP Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · kind: Award of Restricted Stock under the Amended and Restated 2014 Long-Term Incentive Plan that vests in its entirety on December 12, 2023. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 17:39 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock option (right to buy) · Derivative | 9,217 | $1.10 Strike: $1.69 | $10,138.70 |
DisclosureSEC source: 0001209191-18-040676 · doc4.xml · derivative · entry 1 McCourt Marion · CIK 0001663758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,217 Underlying: Common Stock · 9,217 shares Expires 2028-07-01 F1 · price: Stock option received by the Reporting Person pursuant to such Reporting Person's election to receive stock option in lieu of the Reporting Person's annual cash retainers (paid quarterly) under the Compensation Arrangement with Non-Employee Directors policy. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 23:14 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock option (right to buy) · Derivative | 11,800 | $0.86 Strike: $1.32 | $10,148.00 |
DisclosureSEC source: 0001209191-18-023924 · doc4.xml · derivative · entry 1 McCourt Marion · CIK 0001663758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,800 Underlying: Common Stock · 11,800 shares Expires 2028-04-01 F1 · price: Stock option received by the Reporting Person pursuant to such Reporting Person's election to receive stock option in lieu of the Reporting Person's annual cash retainers (paid quarterly) under the Compensation Arrangement with Non-Employee Directors policy. Read SEC document |
| February 12, 2018 Filed Feb 12, 2018 22:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $342.93 | $0.00 |
DisclosureSEC source: 0001237899-18-000010 · edgardoc.xml · derivative · entry 2 McCourt Marion · CIK 0001663758 · SVP Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-02-12 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 12, 2018 Filed Feb 12, 2018 22:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-18-000010 · edgardoc.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · SVP Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · kind: Award of Restricted Stock under the Amended and Restated 2014 Long-Term Incentive Plan that vests in its entirety on February 12, 2023. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:31 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 6,831 | $1.48 Strike: $2.28 | $10,109.88 |
DisclosureSEC source: 0001209191-18-001749 · doc4.xml · derivative · entry 1 McCourt Marion · CIK 0001663758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,831 Underlying: Common Stock · 6,831 shares Expires 2028-01-01 F1 · price: This option was issued to the Reporting Person pursuant to the Issuer's Compensation Arrangement with Non-Employee Directors policy in lieu of the Reporting Person's annual cash retainers (paid quarterly) under such policy. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:30 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 19,989 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001209191-18-001745 · doc4.xml · derivative · entry 1 McCourt Marion · CIK 0001663758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,989 Underlying: Common Stock · 19,989 shares Expires 2028-01-01 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant; provided, that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:29 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 6,332 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001178253-17-000023 · wf-form4_150714894713361.xml · derivative · entry 1 McCourt Marion · CIK 0001663758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,332 Underlying: Common Stock · 6,332 shares Expires 2027-10-02 Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 19:55 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 8,511 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001178253-17-000014 · wf-form4_149928452238964.xml · derivative · entry 1 McCourt Marion · CIK 0001663758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,511 Underlying: Common Stock · 8,511 shares Expires 2027-07-03 Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 17:58 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $13.78 | $0.00 |
DisclosureSEC source: 0001140361-17-025789 · doc1.xml · derivative · entry 1 McCourt Marion · CIK 0001663758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: The option vests in full on June 20, 2018 subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document |
| April 07, 2017 Filed Apr 11, 2017 17:56 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | GrantEmployee Stock Option (Right to Buy) · Derivative | 465,000 | $0.00 Strike: $15.13 | $0.00 |
DisclosureSEC source: 0001209191-17-026602 · doc4.xml · derivative · entry 1 McCourt Marion · CIK 0001663758 · Principal Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,000 Underlying: Common Shares · 465,000 shares Expires 2027-04-07 F1 · derivative.exercise_date: 25% of the common shares underlying the option vest and become exercisable on April 7, 2018; the balance of the common shares vest in a series of 12 successive equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Vesting is subject to acceleration in specified circumstances, including a change in control of the Issuer or the Reporting Person's termination without cause or resignation for good reason. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 18:39 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 5,878 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001178253-17-000004 · wf-form4_149133118107433.xml · derivative · entry 1 McCourt Marion · CIK 0001663758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,878 Underlying: Common Stock · 5,878 shares Expires 2027-04-03 Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 18:18 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001140361-17-014170 · doc1.xml · derivative · entry 1 McCourt Marion · CIK 0001663758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2027-03-28 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from March 31, 2017 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 21:59 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 34,144 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001628280-17-000526 · wf-form4_148555435721998.xml · derivative · entry 1 McCourt Marion · CIK 0001663758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,144 Underlying: Common Stock · 34,144 shares Expires 2027-01-25 F1 · derivative.exercise_date: 2.78% of the shares subject to the option vest monthly for 36 months as measured from the date of grant. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 23:03 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 4,274 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001628280-17-000545 · wf-form4_148555820102113.xml · derivative · entry 1 McCourt Marion · CIK 0001663758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,274 Underlying: Common Stock · 4,274 shares Expires 2027-01-25 Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:52 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 80,905 | Not disclosed Strike: $31.58 | Not disclosed |
DisclosureSEC source: 0001209191-16-143388 · doc4.xml · derivative · entry 3 McCourt Marion · CIK 0001663758 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,905 shares Expires 2026-02-16 F4 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F4 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:52 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerCommon Stock | 40,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-143388 · doc4.xml · nonDerivative · entry 2 McCourt Marion · CIK 0001663758 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F3 · shares: Represents unvested restricted stock units (the "RSUs") that were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. F1 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:52 UTC | MEDIVATION, INC. MDVN · Entity 181987 | OtherCommon Stock | 541 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-143388 · doc4.xml · nonDerivative · entry 1 McCourt Marion · CIK 0001663758 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F2 · shares: Represents shares purchased through the Issuer's Employee Stock Purchase Plan on September 21, 2016. F1 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.